88 205

Cited 13 times in

Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B.

Authors
Kim, SS; Cheong, JY; Cho, SW
Citation
Gut and liver, 5(3):278-287, 2011
Journal Title
Gut and liver
ISSN
1976-22832005-1212
Abstract
Although the prevalence of chronic hepatitis B has decreased considerably in recent years due to widespread use of the hepatitis B virus (HBV) vaccine, its prevalence still remains high in adults, and this can place a significant burden on health care in areas with endemic HBV. Since the introduction of nucleos(t)ide analogues (NUCs), there has been marked improvement in the care of patients with chronic hepatitis B, resulting in increased survival. However, the emergence of drug resistance in patients treated with NUCs is a major concern. The number of multi-drug resistant patients is increasing, and many patients may not respond to the currently available drugs. In this review, we describe the current status of NUC therapy for antiviral-naïve and -resistant patients.
DOI
10.5009/gnl.2011.5.3.278
PMID
21927654
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Gastroenterology
AJOU Authors
김, 순선정, 재연조, 성원
Full Text Link
Files in This Item:
278-287.pdfDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse